發(fā)布時間：2018-11-22 12:25

【摘要】：近年來,對特發(fā)性肺纖維化(IPF)發(fā)病機(jī)制和治療靶點的研究成為熱點。一些細(xì)胞因子與IPF關(guān)系密切,其中轉(zhuǎn)化生長因子-β(TGF-β)引導(dǎo)成纖維細(xì)胞和巨噬細(xì)胞至損傷處,直接誘發(fā)成纖維細(xì)胞轉(zhuǎn)化為肌成纖維細(xì)胞并促進(jìn)膠原合成;血小板源生長因子(PDGF)和堿性纖維母細(xì)胞生長因子(b FGF)與成纖維細(xì)胞增殖有關(guān)。此外,相關(guān)蛋白如賴氨酰氧化酶相關(guān)蛋白2(LOXL2)、ανβ6整合蛋白和溶血磷脂酸1受體(LPA1)等均為新的IPF治療靶點。目前針對IPF治療靶點的藥物相繼進(jìn)入臨床試驗,吡非尼酮(Pirfenidone)為轉(zhuǎn)化生長因子-β(TGF-β)抑制劑;尼達(dá)尼布(Nintedanib)為三重酪氨酸激酶抑制劑,作用于PDGF、VEGF和FGF受體;Simtuzumab是一種人源化單克隆抗體,作用于賴氨酰氧化酶相關(guān)蛋白2(LOXL2),阻斷膠原交聯(lián),正處于IPFⅡ期臨床試驗。STX-100是一種人源化ανβ6特異性單克隆抗體,與ανβ6整合蛋白結(jié)合,阻止后者激活TGF-β。
[Abstract]:In recent years, the research on the pathogenesis and therapeutic targets of idiopathic pulmonary fibrosis (IPF) has become a hot topic. Some cytokines are closely related to IPF, among which transforming growth factor- 尾 (TGF- 尾) guides fibroblasts and macrophages to the injured site, directly induces fibroblasts into myofibroblasts and promotes collagen synthesis. Platelet-derived growth factor (PDGF) and basic fibroblast growth factor (b FGF) are associated with fibroblast proliferation. In addition, the related proteins such as lysyl oxidase associated protein 2 (LOXL2), 偽 謂 尾 6 integrin and lysophosphatidic acid 1 receptor (LPA1) are new targets for IPF therapy. At present, the drugs targeted at the target of IPF have entered the clinical trials. Pifenidone (Pirfenidone) is a transforming growth factor- 尾 (TGF- 尾) inhibitor, and NIDNIBE (Nintedanib) is a triple tyrosine kinase inhibitor acting on PDGF,VEGF and FGF receptors. Simtuzumab is a humanized monoclonal antibody acting on lysyl oxidase associated protein 2 (LOXL2), blocking collagen crosslinking, and is in clinical trial stage 鈪，

本文編號：2349369